Previous 10 | Next 10 |
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Company will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference. Presentations w...
BeiGene is planning an IPO on the Shanghai Star Exchange that could raise up to $2.5 billion. BeiGene announced China approval to market Xgeva (denosumab) to prevent skeletal-related events (SREs) in patients with bone metastases from solid tumors or multiple myeloma. LianBio, a P...
BeiGene's (BGNE) XGEVA (denosumab) has been approved in China for the prevention of skeletal-related events in patients with bone metastases from solid tumors and in patients with multiple myeloma ((MM)).XGEVA is developed by Amgen (AMGN) and licensed to BeiGene in China under ...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the China National Medical Products Administration (NMPA) has approved XGEVA ® (denosumab) for the ...
As recommended by the independent Data Monitoring Committee, BeiGene ([[BGNE]] +1.8%) has announced interim data from Phase 3 (RATIONALE 303) trial evaluating tislelizumab versus docetaxel in the second- or third-line setting in patients with locally advanced or metas...
RATIONALE 303 is a global Phase 3 trial of BeiGene’s anti-PD-1 antibody tislelizumab compared to docetaxel in the second- or third-line setting in patients with locally advanced or metastatic non-small cell lung cancer who progressed on prior platinum-based chemotherapy ...
Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic Demonstration Area. Decheng Capital had good reason to be pleased when Merck paid $2.75 billion...
Under priority review status, China's National Medical Products Administration has accepted BeiGene's ([[BGNE]] -2.5%) marketing application seeking approval of dinutuximab beta for the treatment of high-risk neuroblastoma patients at least 12 years old.The targeted immunotherapy, branded as ...
BeiGene (BGNE): Q3 GAAP EPADS of -$4.81 misses by $0.59.Revenue of $91.08M (+81.7% Y/Y) beats by $8.59M.Press Release For further details see: BeiGene EPS misses by $0.59, beats on revenue
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported recent business highlights, anticipated upcoming milestones, and financial results for the third quarter and first...
News, Short Squeeze, Breakout and More Instantly...
BeiGene Ltd. Company Name:
BGNE Stock Symbol:
NASDAQ Market:
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
With the earnings season in full swing, these large-cap stocks were the best performers in the last week. Are they in your portfolio? Vertiv Holdi...
Newly released report details Company’s achievements and plans for sustainable growth BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, released its 2023 Responsible Business & Sustainability Report highlighting the Company’s strategy, ...